Galectin Therapeutics Ownership | Who Owns Galectin Therapeutics?


OverviewForecastFinancialsChart

Galectin Therapeutics Ownership Summary


Galectin Therapeutics is owned by 8.65% institutional investors, 29.10% insiders, and 62.25% retail investors. Vanguard group is the largest institutional shareholder, holding 3.56% of GALT shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.31% of its assets in Galectin Therapeutics shares.

GALT Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockGalectin Therapeutics8.65%29.10%62.25%
SectorHealthcare Stocks 35.64%12.08%52.28%
IndustryBiotech Stocks 35.43%12.01%52.56%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group2.29M3.56%$9.52M
Blackrock1.56M2.52%$3.53M
Marshall wace, llp1.22M1.91%$3.40M
Advisor group1.12M1.76%$3.13M
Blackrock funding, inc. /de799.24K1.25%$2.23M
Millennium management798.43K1.25%$2.23M
Wealthspire advisors721.79K1.13%$2.01M
Geode capital management612.79K0.96%$1.71M
Susquehanna group, llp555.70K0.87%$1.55M
Two sigma investments, lp467.06K0.73%$1.30M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Retirement guys formula187.06K0.24%$521.90K
Solutions 4 wealth25.03K0.10%$69.83K
Vivaldi capital management lp258.58K0.10%$721.45K
Sovran advisors257.83K0.05%$585.27K
Fortis capital advisors106.14K0.04%$296.13K
Argyle capital partners13.38K0.03%$37.32K
683 capital management162.48K0.02%$453.33K
Wealthspire advisors721.79K0.02%$2.01M
Geneos wealth management240.93K0.02%$672.19K
Gsa capital partners llp71.42K0.01%$199.00K

Top Buyers

HolderShares% AssetsChange
Blackrock1.56M0.00%851.14K
Marshall wace, llp1.22M0.00%617.78K
Millennium management798.43K0.00%562.93K
Two sigma investments, lp467.06K0.00%450.45K
Vanguard fiduciary trust304.24K0.00%304.24K

Top Sellers

HolderShares% AssetsChange
Y-intercept (hong kong)---235.19K
Atria wealth solutions---186.00K
Morgan stanley104.41K--174.88K
Wellington management group llp---142.22K
Soltis investment advisors---140.75K

New Positions

HolderShares% AssetsChangeValue
Vanguard fiduciary trust304.24K0.00%304.24K$848.83K
Renaissance147.90K0.00%147.90K$412.64K
Hrt financial lp51.06K0.00%51.06K$142.00K
Wiley bros.-aintree capital41.00K0.00%41.00K$114.39K
Brevan howard capital management lp35.59K0.00%35.59K$99.28K

Sold Out

HolderChange
Eversource wealth advisors-1.00
True wealth design-2.00
Sbi securities-5.00
Legal & general group-38.00
Srs capital advisors-52.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202644-56.86%5,526,312-52.22%82.67%22-59.26%9-59.09%
Dec 31, 202569-22.47%8,887,115-13.85%135.24%32-11.11%17-37.04%
Sep 30, 202587-3.33%10,009,146-4.34%155.76%35-5.41%2618.18%
Jun 30, 202588-7.37%9,965,1580.59%156.42%3624.14%22-26.67%
Mar 31, 202594-14.55%9,893,813-1.83%155.98%30-53.13%29222.22%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.52M2.31%170.00K
Vanguard US Total Market Shares ETF1.25M1.97%-
iShares Russell 2000 ETF957.15K1.45%5.68K
Vanguard Institutional Extnd Mkt Idx Tr595.15K0.90%448.00
iShares Russell 2000 Growth ETF308.69K0.47%-1.19K
Russell 2000 Equity Index Fund B288.97K0.44%288.97K
Russell 2000 Index Non-Lendable Fund288.97K0.44%288.97K
Vanguard Russell 2000 ETF275.02K0.42%275.02K
Fidelity Extended Market Index271.58K0.41%-5.15K
State St Russell Sm Cap® Idx SL Cl I178.10K0.27%178.10K

Recent Insider Transactions


DateNameRoleActivityValue
Jul 14, 2026Jamil Khurram Chief Medical OfficerSell$83.28K
Jun 29, 2026Shlevin Harold H.-Sell$112.23K
Jun 26, 2026Shlevin Harold H.-Sell$38.66K
Jun 26, 2026Jamil Khurram Chief Medical OfficerSell$12.66K
Jun 29, 2026Jamil Khurram Chief Medical OfficerSell$239.23K

Insider Transactions Trends


DateBuySell
2026 Q3-1
2026 Q2-6
2026 Q119
2025 Q4239
2025 Q322

GALT Ownership FAQ


Who Owns Galectin Therapeutics?

Galectin Therapeutics shareholders are primarily institutional investors at 8.65%, followed by 29.10% insiders and 62.25% retail investors. The average institutional ownership in Galectin Therapeutics's industry, Biotech Stocks , is 35.43%, which Galectin Therapeutics falls below.

Who owns the most shares of Galectin Therapeutics?

Galectin Therapeutics’s largest shareholders are Vanguard group (2.29M shares, 3.56%), Blackrock (1.56M shares, 2.52%), and Marshall wace, llp (1.22M shares, 1.91%). Together, they hold 8.00% of Galectin Therapeutics’s total shares outstanding.

Does Blackrock own Galectin Therapeutics?

Yes, BlackRock owns 2.52% of Galectin Therapeutics, totaling 1.56M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 3.53M$. In the last quarter, BlackRock increased its holdings by 851.14K shares, a 119.44% change.

Who is Galectin Therapeutics’s biggest shareholder by percentage of total assets invested?

Retirement guys formula is Galectin Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.24% of its assets in 187.06K Galectin Therapeutics shares, valued at 521.9K$.

Who is the top mutual fund holder of Galectin Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Galectin Therapeutics shares, with 2.31% of its total shares outstanding invested in 1.52M Galectin Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools